Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, announced the completion of a $45 million Series B financing. Kurma Partners and Angelini Ventures co-led the funding round, which was significantly participated in by existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund, along with Highlight Capital and SEEDS Capital.
LMNA DCM: LMNA DCM is a genetic heart condition caused by mutations in the LMNA gene. It leads to the weakening and enlargement of the heart muscle, resulting in a rapid progression toward end-stage heart failure. LMNA DCM is estimated to affect over 100,000 patients in the U.S. and Europe. NVC-001 and other pipeline assets are derived from Nuevocor’s proprietary PrOSIATM mechanobiology platform, which pinpoints the functional root cause of many cardiomyopathies.
What the funding will be used for: The new funding will support a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM, with clinical trial sites across the U.S. and Europe. Additionally, the company will establish an office in Paris, France, to support clinical development and bring Singapore innovation to patients globally.
New board members: Nuevocor also welcomes Amanda Gett-Chaperot, PhD (Kurma Partners) and Elia Stupka, PhD (Angelini Ventures) to its Board of Directors.
KEY QUOTES:
“We are delighted to secure this significant financing milestone to build a global company with such an experienced syndicate of international life science investors. The continued strong support from insiders and the addition of new investors will enable Nuevocor to continue its strong momentum and advance NVC-001 into the clinic. This is an example of how Singapore is bringing transformative innovation to the rest of the world.”
Dr. Yann Chong Tan, PhD, CEO and Co-Founder of Nuevocor
“Nuevocor is providing new hope to a significant population of cardiovascular patients who today lack treatment options by directly targeting the underlying causes of disease. The burden of cardiomyopathies is large, and Kurma is excited to join Nuevocor, investing from our new Biofund IV to create meaningful value through the treatment of these important diseases.”
Dr. Amanda Gett-Chaperot, Partner at Kurma Partners
“Our investment in Nuevocor marks a strategic expansion for Angelini Ventures – into cardiovascular disease, gene therapy, and the Singapore biotech ecosystem. We are excited by Nuevocor’s novel approach to treating genetic-dilated cardiomyopathy by targeting mechanobiological pathways rather than simply replacing genes. This one-time therapy has the potential to transform patient outcomes and ease healthcare burdens. We are proud to support their mission and join the Board, alongside Kurma, ClavystBio, EDBI, Boehringer Ingelheim Venture Fund, and other investors, as the company grows globally, including into Europe.”
Dr. Elia Stupka, Managing Director at Angelini Ventures
